Dibenzocyclooctadiene lignans - A class of novel inhibitors of multidrug resistance-associated protein 1

Life Sciences

Volumn 80, Issue 8, 2007, Pages 741-748

  Li, Ling ^a   Pan, Qiangrong ^a   Sun, Meng ^a   Lu, Qinghua ^a   Hu, Xun ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cancer multidrug resistance; Dibenzocyclooctadiene; Multidrug resistant associated protein 1

Indexed keywords

DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; GOMISIN A; MULTIDRUG RESISTANCE PROTEIN 1; PROBENECID; SCHISANDRIN A; SCHISANDRIN B; SCHISANDROL A; SCHISANTHERIN A; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL STRAIN HL 60; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PROMYELOCYTIC LEUKEMIA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CYCLOOCTANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HL-60 CELLS; HUMANS; LIGNANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEINS;

EID: 33846233855     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.11.002     Document Type: Article

References (39)

1. Baer M.R., George S.L., Dodge R.K., O'Loughlin K.L., Minderman H., Caligiuri M.A., Anastasi J., Powell B.L., Kolitz J.E., Schiffer C.A., Bloomfield C.D., and Larson R.A. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100 4 (2002) 1224-1232
2. Boesch D., Muller K., Pourtier-Manzanedo A., and Loor F. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Experimental Cell Research 196 1 (1991) 26-32
3. Campling B.G., Young L.C., Baer K.A., Lam Y.M., Deeley R.G., Cole S.P., and Gerlach G.H. Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clinical Cancer Research 3 1 (1997) 115-122
4. Chiu P.Y., and Ko K.M. Schisandrin B protects myocardial ischemia-reperfusion injury partly by inducing Hsp25 and Hsp70 expression in rats. Molecular and Cellular Biochemistry 266 (2004) 139-144
5. Cole S.P., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M., and Deeley R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258 5088 (1992) 1650-1654
6. Deeley R.G., Westlake C., and Cole S.P.C. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiological Review 86 (2006) 849-899
7. Dogan A.L., Legrand O., Faussat A.M., Perrot J.Y., and Marie J.P. Evaluation and comparison of MRP1 activity with three fluorescent dyes and three modulators in leukemic cell lines. Leukemia Research 28 6 (2004) 619-622
8. Endicott J.A., and Ling V. The biochemistry of P-glycoprotein mediated multidrug resistance. Annual Review Biochemistry 58 (1989) 137-171
9. Gottesman M.M., and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annual Review Biochemistry 62 (1993) 385-427
10. Gottesman M.M., Fojo T., and Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Reviews Cancer 2 1 (2002) 48-58
11. Greenberg P.L., Lee S.J., Advani R., Tallman M.S., Sikic B.I., Letendre L., Dugan K., Lum B., Chin D.L., Dewald G., Paietta E., Bennett J.M., and Rowe J.M. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). Journal of Clinical Oncology 22 6 (2004) 1078-1086
12. Hanck J.L., Burgos R.A., and Ahumanda F. Schisandra chinensis(Turcz) Bail. Fitoterpia 70 (1999) 451-471
13. Herzog C.E., Tsokos M., Bates S.E., and Fojo A.T. Increased mdr-1/ P-glycoprotein expression after treatment of human coloncarcinoma cells with P-glycoprotein antagonists. Journal of Biological Chemistry 268 (1993) 2946-2952
14. Hipfner D.R., Deeley R.G., and Cole S.P. Structural, mechanistic and clinical aspects of MRP1. Biochimica et Biophysica Acta 1461 2 (1999) 359-376
15. Ip S.P., Poon M.K., Wu S.S., Che C.T., Ng K.H., Kong Y.C., and Ko K.M. Effect of schisandrin B on hepatic glutathione antioxidant system in mice: protection against carbon tetrachloride toxicity. Planta Medica 61 5 (1995) 398-401
16. Ko K.M., and Lam B.Y. Schisandrin B protects against tertbutylhydro-peroxide induced cerebral toxicity by enhancing glutathione antioxidant status in mouse brain. Molecular and Cellular Biochemistry 238 (2002) 181-186
17. Legrand O., Simonin G., Beauchamp-Nicoud A., Zittoun R., and Marie J.P. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood 94 (1999) 1046-1056
18. Leslie E.M., Deeley R.G., and Cole S.P.C. Bioflavonoid stimulation of glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). Drug Metabolism and Disposition 31 (2003) 11-15
19. Li L., Lu Q., and Hu X. Schisandrin B enhances doxorubicin-induced apoptosis of cancer cells but not normal cells. Biochemical Pharmacology 71 5 (2006) 584-595
20. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemotherapy and Pharmacology 40 (1997) S3-S8
21. List AF., Spier C.S., Grogan T.M., Johnson C., Roe D.J., Greer J.P., Wolff S.N., Broxterman H.J., Scheffer G.L., Scheper R.J., and Dalton W.S. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87 (1996) 2464-2469
22. List A.F., Kopecky K.J., Willman C.L., Head D.R., Persons D.L., Slovak M.L., Dorr R., Karanes C., Hynes H.E., Doroshow J.H., Shurafa M., and Appelbaum F.R. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98 12 (2001) 3212-3220
23. Loe D.W., Deeley R.G., and Cole S.P. Biology of the multidrug resistance protein, MRP. European Journal of Cancer 32A 6 (1996) 945-957
24. Marbeuf-Gueye C., Broxterman H.J., Dubru F., Priebe W., and Garnier-Suillerot A. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells. Molecular Pharmacology 53 (1998) 141-147
25. Minderman H., Brooks T.A., O'Loughlin K.L., Ojima I., Bernacki R.J., and Baer M.R. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023. Cancer Chemotherapy and Pharmacology 53 5 (2004) 363-369
26. Minderman H., O'Loughlin K.L., Pendyala L., and Baer MR. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clinical Cancer Research 10 5 (2004) 1826-1834
27. Nakanishi T., Karp J.E., Tan M., Doyle L.A., Peters T., Yang W., Wei D., and Ross D.D. Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clinical Cancer Research 9 (2003) 3320-3328
28. Narasaki F., Oka M., Fukuda M., Nakano R., Ikeda K., Takatani H., Terashi K., Soda H., Yano O., Nakamura T., Doyle L.A., Tsuruo T., and Kohno S. A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene. Cancer Chemotherapy and Pharmacology 40 5 (1997) 425-432
29. Nicholson K.M., Quinn D.M., Kellett G.L., and Warr J.R. LY294002, an inhibitor of phosphatidylinositol-3-kinase, causes preferential induction of apoptosis in human multidrug resistant cells. Cancer Letters 190 1 (2003) 31-36
30. Palissot V., Morjani H., Belloc F., Cotteret S., Dufer J., and Berchem G. From molecular characteristics to cellular events in apoptosis-resistant HL-60 cells. International Journal of Oncology 26 3 (2005) 825-834
31. Pan Q., Lu Q., Zhang K., and Hu X. Dibenzocyclooctadiene lignans - a class of novel inhibitors of P-glycoproteins. Cancer Chemotherapy and Pharmacology 58 1 (2006) 99-106
32. Pommier Y., Sordet O., Antony S., Harward R.L., and Kohn K.W. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23 16 (2004) 2934-2949
33. Qadir M., O'Loughlin K.L., Fricke S.M., Williamson N.A., Greco W.R., Minderman H., and Baer M.R. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clinical Cancer Research 11 (2005) 2320-2326
34. Qiangrong P., Wang T., and Hu X. Schisandrin B - a novel inhibitor of P-glycoprotein. Biochemical and Biophysical Research Communications 335 2 (2005) 406-411
35. Robert J., and Jarry C. Multidrug resistance reversal agents. Journal of Medicinal Chemistry 46 23 (2003) 4805-4817
36. Schinkel A.H., and Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Advanced Drug Delivery Reviews 55 1 (2003) 3-29
37. Sun M., Xu X.L., Lu Q., Pan Q., and Hu X. Schisandrin B - a dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1. Cancer Letters (2006) (E-pub ahead of print)
38. Suvannasankha A., Minderman H., O'Loughlin K.L., Nakanishi T., Greco W.R., Ross D.D., and Baer M.R. Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function. Leukemia 18 (2004) 1252-1257
39. Varadi A., Szakacs G., Bakos E., and Sarkadi B.P. Glycoprotein and the mechanism of multidrug resistance. Novartis Foundation Symposium 243 (2002) 54-65